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Introduction
Spinal muscular atrophy (SMA) is one of the most fre-
quent autosomal recessive childhood diseases. It is caused by 
mutations of the SMN1 gene [1, 2]. SMA patients present with 
progressive muscle weakness and atrophy [3]. SMA coexist-
ing with another genetic entity is extremely rare, and poses 
a diagnostic challenge. These so-called “double trouble” cases 
demand a carefully tailored approach and multidisciplinary 
management. Here, we present two new cases of SMA overlap-
ping with hereditary spastic paraplegia and Noonan syndrome, 
as well as a follow-up to our previously reported patient with 
SMA and Charcot-Marie-Tooth 1A [4]. 
Case report 1
We present the case of a 17-year-old girl with a history of 
progressive walking difficulties since the age of five. When she 
was four, her parents first noticed a tendency towards tiptoe 
walking. There was a history of progressive walking difficulties 
in several family members from her father’s side (Pedigree 1) 
who presented with pure spastic paraplegia. Molecular test-
ing revealed the c.1729-2A>G point mutation in the spastin 
gene (SPAST), confirming the diagnosis of hereditary spastic 
paraplegia (HSP). This mutation was present in our proband 
as well. However, in the neurological examination, she mani-
fested additional symptoms. Moderate proximal weakness of 
her lower and upper limbs was observed. She had an increased 
muscle tone in her lower limbs, with brisk ankle reflexes and 
pes cavus (Fig. 1), but her knee reflexes were absent. Finger 
and tongue tremors were reported. Her nerve conduction 
study results were normal. Concentric needle electromyograp-
hy revealed some neurogenic changes (supplementary Fig. 
2). A genetic test confirmed homozygous deletion of exons 
7 and 8 of the SMN1 gene and three copies of the SMN2 gene.
Figure 1. Foot deformity in patient with spinal muscular atrophy 
and hereditary spastic paraplegia
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Table 1. Summary of Noonan syndrome features present in patient
Dysmorphic features Hypertelorism, ptosis, low-set ears, high 
forehead, triangular face, broad neck, 
widely spaced nipples
Cardiac defects Pulmonary valve stenosis
Musculoskeletal defects Short stature (postnatal onset), pectus 
excavatum, scoliosis 
Neurological defects Learning difficulties, mild developmental 
delay
Ocular abnormalities Nystagmus, myopia
Bleeding diathesis Easy bruising
Neonatal features Dorsal limb lymphedema
Case report 2
We present the case of a 20-year-old man who had been 
delivered by caesarean section in the 36th week of gestation 
(premature rupture of the membranes). In his first days of life, 
he had some breathing difficulties, manifested cyanosis, and was 
diagnosed with pulmonary stenosis. The patient underwent bal-
loon plastic surgery a few months later. He had some dysmorphic 
features: hypertelorism, low-set ears, a high forehead, a broad 
neck, bilateral ptosis, widely spaced nipples, and a high arched 
palate (supplementary Fig. 3). His motor milestones were re-
ported as normal; however, from the start he could not keep up 
with his peers. When he was 17, a diagnosis of Noonan syndrome 
was established and confirmed through genetic testing. He car-
ries the c.922A>G (Asn308Asp) mutation in PTPN11 gene, de 
novo in its origin. He was referred to our centre for evaluation 
of proximal muscle weakness at the age of 17.  Since the age of 
six there had been a tendency towards tiptoe walking and some 
difficulties with climbing stairs. On examination, he presented 
with hypotonia, proximal weakness more prominent in the lower 
than in the upper limbs, a waddling gait, Gower’s sign, and bi-
laterally absent knee reflexes. Neither finger nor tongue tremors 
were observed. His nerve conduction study was normal, whereas 
his electromyography and muscle biopsy were consistent with 
neurogenic changes (supplementary Fig. 4). The clinical diagno-
sis of spinal muscular atrophy was confirmed by the detection of 
a homozygous absence of the SMN1 copy in exon 7. Interestingly, 
exon 7 was found to be deleted from one copy of SMN1 in one 
parent only – the mother (Pedigree 2). Recently, this patient has 
experienced decreased tolerance for motor activities, a finding 
initially attributed to progression of SMA. A cardiological evalu-
ation revealed a reoccurrence of severe pulmonary stenosis, and 
now the patient is awaiting his second cardiac surgery. His neu-
romuscular performance is stable. The features of NS syndrome 
in our patient are summarised in Table 1.
Case report 3 
Table 2 shows summary of the patients’ clinical details.
See supplementary files.
Discussion
To the best of our knowledge, there is no modern report of 
a coincidence of HSP and SMA, nor of NS and SMA.
SMA + HSP
Hereditary spastic paraplegia (HSP) is a heterogenous 
group of diseases with a prevalence of 1.8/100,000 [9]. 
Progressive lower limb spasticity and muscle weakness 
are its most prominent features. Most frequently, the first 
symptoms occur in adulthood. Our understanding of the 
genetic background spectrum has expanded considerably in 
recent decades. Mutations of over 70 distinct loci have been 
identified, with the spastin gene mutation being the most 
common cause of HSP that is classified as familial spastic 
paraplegia 2 (FSP2) [10]. In spastic paraplegia 4 (SPG4) 
spasticity may be accompanied by a reduced vibration in 
the legs. Theoretically, a mild spasticity may be beneficial in 
patients with SMA. Also, a lower motor neuron lesion may 
ameliorate an increased muscle tone. Such an additive effect 
has been reported in SPG4 coexisting with facioscapulohu-
meral muscular dystrophy [11]. Most probably, that positive 
effect could be merely temporal due to progressive spasticity 
and SMA-related weakness. 
SMA + NS
Noonan syndrome (NS) is a common heterogenic disorder 
featuring characteristic facial features, a high incidence of con-
genital cardiac defects, short stature, chest deformities as well 
as cryptorchidism in males, mild intellectual deficits, bleeding 
tendencies, and many others. The estimated incidence of NS 
is 1:1,000 live births [12]. The diagnosis is based on a clinical 
scoring system introduced by van der Burgt (supplemen-
tary Tab. 3) [13]. Genetic testing confirms the diagnosis in 
approximately 70% of cases. About half of cases are caused by 
a mutation in the protein tyrosine phosphatase nonreceptor 
type 11 (PTPN11) gene [14]. 
In the literature, there is one case report describing a pa-
tient with NS and Becker muscular dystrophy (BMD) with 
a more severe phenotype resembling Duchenne’s muscular 
dystrophy [15]. Hypotonia features early in NS and accounts 
for mild motor delays [13]. Children with NS start walking 
independently on average at around 21 months [16]. One 
study assessed motor function in 19 children with NS aged 
6 to 11. They showed reduced grip and muscle strength. 
The mean distance in a six-minute walking test (6MWT) 
differed from reference values (p < 0.001) [17]. One of the 
factors influencing their physical activity was congenital 
heart disease. The intensity of physiotherapy in our patient 
had also to be reduced because of significant pulmonary 
stenosis. That further compromised his motor functions, 
already impaired by SMA. 
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SMA + CMT 
See supplementary files.
Conclusion 
Coincidences of SMA and another genetic disorder are 
very rare. The symptoms of anterior horn dysfunction should 
keep physicians away from using Occam’s razor in the diag-
nostic process. With the emergence of pharmacological treat-
ment in SMA, heightened attention is needed when a patient 
presents with such symptoms complicated by the coexistence 
of another genetic disease. 
Clinical implications/future directions
Diagnosing SMA should lead to a therapeutic intervention 
[19–22]. Other medical problems should be attended to as 
required. We hope that opportunities to change the course 
of SMA in overlapping syndromes may turn “double trouble” 
into “single trouble” cases.
Legend and abbreviations
Pedigree 1: SMA — spinal muscular atrophy; SPG4 — 
spastic paraplegia 4
Pedigree 2: SMA — spinal muscular atrophy; NS — 
Noonan syndrome
Pedigree 3: SMA — spinal muscular atrophy; CMT1A — 
Charcot-Marie-Tooth disease type 1A
Table 2. Summary of the patients’ clinical details
Table 3. NS criteria adapted from van der Burgt [12, 13]
Figure 2. Electromyography results — Case 1. Amp — am-
plitude; Dur — duration; Poly — polyphasia; uV— microvolt; 
rel.SD — relative standard deviation; ms — milliseconds; min 
— minimum; max — maximum
Figure 3. Patient with Noonan syndrome and SMA. 
Note hypertelorism, ptosis, low-set ears, triangular face, 
widely spaced nipples, and proximal muscle wasting of 
upper limbs
Figure 4. Electromyography results — Case 2. Amp 
— amplitude; Dur — duration; Poly — polyphasia; uV 
— microvolt; rel.SD — relative standard deviation; ms — 
milliseconds; min — minimum; max — maximum
Figure 5. Nerve conduction study — Case 3. Lat — 
latency; Amp — amplitude; CV — conduction velocity; 
F-M — F wave; uV — microvolt; ms — milliseconds; SD — 
standard deviation; APB — abductor pollicis brevis muscle; 
Be — below; Ab — above; elb — elbow; ADM — abductor
digiti minimi muscle; AHB — abductor hallucis brevis
muscle; EDB — extensor digitorum brevis muscle
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